• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 281

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Karina Bashir on Psychedelics, Islam, and Human Rights

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Psychedelic Funding Update: Q2 2025

Revive Therapeutics Acquires Unique Psilocybin Assets

PharmaTher Announces Sale of Psilocybin Program

Video Roundtable: The Future of Ketamine Therapy

MindMed’s LSD Neutralizer Study Begins

MindMed’s LSD Neutralizer Study Begins

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s...

Field Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results

The Ultimate Guide to Pets and Psychedelics

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Delineates Parameters...

Cambridge City Councilors Approve Psychedelics Decriminalization Measure

1...280281282...292Page 281 of 292

EDITOR PICKS

Karina Bashir on Psychedelics, Islam, and Human Rights

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©